New China Capital Management

New China Capital Management oversees the Cathay family of funds, which specialize in providing growth equity to Chinese companies across various industries, including consumer products, financial services, technology, and infrastructure. Established in 1992, the firm has successfully executed over 40 investments and facilitated numerous initial public offerings and trade sales, with a cumulative transaction value exceeding $5 billion. With assets under management surpassing $1.5 billion, New China Capital Management acts as a lead equity investor, offering essential capital that enables portfolio companies to expand operations, enhance competitiveness, and explore new business opportunities. The firm also provides expertise in restructuring when necessary, supporting companies in optimizing their operations and preparing for significant capital events.

Anita Eng

Chief Financial Officer

Hermann Leung

Operating Partner

Ling M. Liu

Managing Director

Paul S. Wolansky

Chairman and Chief Executive Officer

Wai Wai Wong

Vice President

Michael Xie

Investment Professional

Alice Fan Yang

Assistant President

Rongrong Zhang

Vice President

4 past transactions

Shanghai Henlius Biotech

Venture Round in 2018
Shanghai Henlius Biotech, Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the research, development, production, and commercialization of biologics, particularly monoclonal antibody (mAb) biosimilars and novel mAbs. Founded in 2010 and operating within the Shanghai Caohejing High-Technology Park, the company focuses on addressing oncology and autoimmune diseases on a global scale. Its lead product, HLX01, is a biosimilar of rituximab aimed at treating non-Hodgkin lymphoma. Currently, the company has several products under new drug application review and is conducting around 20 clinical studies for various therapies. Additionally, Henlius is collaborating with other biopharmaceutical firms to develop treatments for COVID-19 and eye diseases, including a recombinant humanized anti-VEGF monoclonal antibody for wet age-related macular degeneration. As a joint venture between Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals, Shanghai Henlius Biotech exemplifies innovation in the biopharmaceutical sector.

Weidai

Series C in 2016
Weidai is an early stage personal credit system based in China. As a peer-to-peer lending service that uses vehicles as collateral, Weidai plans to expand to use property as collateral and provide personal loans as well.

Yaochufa

Series D in 2016
Yaochufa company founded in October 2011, the company mainly to provide "travel around" package services, that is to big cities or the capital city as the center, covering its neighboring cities and neighboring provinces tourism market, itinerary 1 - 1 day based tourism packages. Within the package covers the cream of the crop of artificial selection of boutique resort, as well as specialty restaurants, tourist attractions tickets and many other essential products, so the quality of tourism products within the package can be maintained 4-5 star or more. To travel around the current online packages starting about 2000, all the packages are suitable for families and parents and children around the tour.

UCAR

Series B in 2015
UCAR, established in 1999 and headquartered in Tianjin, China, is a leading provider of chauffeured car services in the country. The company operates an on-demand car-hailing platform that connects customers with local drivers through mobile technology. UCAR offers both chauffeured car services and vehicle rentals, utilizing an in-house fleet alongside licensed local drivers. The company's commitment to safety and quality is evident in its rigorous driver background checks, vehicle condition monitoring, and the use of advanced technologies to track driver behavior. UCAR also emphasizes customer privacy and provides quick compensation for accidents, ensuring a reliable and secure experience for users.